Latest Results Presented on ARMO’s Lead Immunotherapy Candidate, AM0010
News
Combining ARMO BioSciences‘ AM0010, or PEGylated Interleukin-10, with immune checkpoint inhibitors induces better objective response rates and disease control rates in kidney cancer patients, than any of the drugs alone, according to new data ... Read more